

**Effects of Intraperitoneal Installation  
of Propranolol on Vascular Smooth  
Muscle Cell (VEGF) Expression in Rat  
Model of Surgically Induced  
Endometriosis**

*Thesis*

*Submitted for Partial Fulfillment of Master Degree  
in Obstetric and Gynecology*

*Presented by*

**Naglaa Mouloud Salem Emssalem**  
(M.B., B.Ch.)

*Under Supervision of*

**Prof. Dr. Karam Mohammed Bayoumi  
Mansour**

Professor of Obstetric and Gynecology  
Faculty of Medicine – Ain-Shams University

**Dr. Mohammed Mahmoud Abd El-Aleem  
Abd-El-Salam**

Lecturer of Obstetric and Gynecology  
Faculty of Medicine – Ain-Shams University

**Dr. Ahmed Mohamed Abdellah**

Director of Animal Research and Experimental Surgery  
Medical Research Center - Ain-Shams University

**Faculty of Medicine  
Ain Shams University  
2015**

# **دراسة الآثار الناتجة عن الحقن المتكرر للبروبرانولول تطبيقاً علي نموذج الفأر التجريبي بعد التدخل الجراحي عقب الإصابة بإنتباز باطن الرحم**

## **رسالة**

توطئة للحصول على درجة الماجستير في التوليد وأمراض النساء

## **مقدمة من**

**الطبيبة / نجلاء مولود سالم**

بكالوريوس الطب والجراحة - ٢٠١٠

## **تحت إشراف**

**أ.د/ كرم محمد بيومي منصور**

أسناد التوليد وأمراض النساء

كلية الطب - جامعة عين شمس

**د/ محمد محمود عبد العليم عبد السلام**

مدرس التوليد وأمراض النساء

كلية الطب - جامعة عين شمس

**د/ أحمد محمد عبد اللاه**

مركز البحوث الطبية

كلية الطب - جامعة عين شمس

**كلية الطب**

**جامعة عين شمس**

**٢٠١٥**



*First of all I wish to express my greatest thanks to **ALLAH**; the most Gracious and Merciful; for giving me the will and strength to fulfill this work,*

*I want to express my profound and sincere gratitude to **Prof. Dr. Karam Mohammed Bayoumi Mansour**, Professor of Obstetric and Gynecology, Faculty of Medicine, Ain-Shams University, for his kind support and supervision of this work,*

*My deepest thanks and gratitude to **Dr. Mohammed Mahmoud Abd El-Aleem Abd-El-Salam**, Lecturer of Obstetric and Gynecology, Ain-Shams University, for his time and efforts in supervision of this work.*

*I would like to express my appreciation and respect to **Dr. Ahmed Mohamed Abdellah**, Director of Animal Research and Experimental Surgery, Ain Shams University, for his great science, knowledge and information.*

*Last but not least, sincere gratitude to **My family** for their spiritual support.*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

# قَالَ

سَبَّحَانَكَ لَا إِلَهَ إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

## **Epidemiology:**

The exact prevalence of endometriosis in the population today is difficult to determine because it is asymptomatic or subclinical in the majority of cases. The prevalence has been estimated to be as low as 1% among asymptomatic women and as high as 60% in women with chronic pelvic pain (*Abbas et al., 2012; Janssen et al., 2013*).

In women with infertility, the prevalence ranges from 20-50% (*Balasch et al., 1996*). This may be due to the fact that endometriosis plays a causative role in infertility, but it also may be due to a diagnostic selection bias, as women with infertility typically undergo laparoscopy as part of their clinical evaluation (*Sundheimer et al., 2014*). Endometriosis is present in 71-87% of women with chronic pelvic pain (*Ling, 1999*).

Between the years 1965 and 1984, endometriosis increased from 10-19% as the primary indication for hysterectomy in the USA. Interestingly, this happened during a time in which a trend towards more conservative therapies as treatment modalities for endometriosis occurred (*National Center for Health Statistics, 1987*). This finding suggests a true increase in the incidence of the disease (*Sundheimer et al., 2014*).

# Contents

Subjects	Page
List of abbreviations.....	II
List of Figures .....	III
List of Tables .....	IV
• <b>Introduction</b> .....	1
• <b>Aim of the Study</b> .....	4
• <b>Review of Literature</b>	
♦ <b>Chapter (1): Endometriosis</b> .....	5
♦ <b>Chapter (2): Vascular Endothelial Growth Factor</b> .....	41
♦ <b>Chapter (3): <math>\beta</math>-Blockers</b> .....	53
• <b>Material and Methods</b> .....	66
• <b>Results</b> .....	73
• <b>Discussion</b> .....	93
• <b>Summary</b> .....	99
• <b>References</b> .....	101
• <b>Arabic Summary</b>	

## List of Abbreviations

<b>AAG</b>	: $\alpha$ 1-acid glycoprotein
<b>ASRM</b>	: Reproductive Medicine
<b>bFGF</b>	: Basic fibroblast growth factor
<b>DIE</b>	: Deep infiltrating endometriosis
<b>ERK</b>	: Extracellular-signal-regulated kinase
<b>ESHRE</b>	: The European Society of Human Reproduction and Embryology
<b>flt</b>	: fms-lime tyrosine kinase
<b>FSH</b>	: Follicle stimulating hormone
<b>GnRH</b>	: Gonadotropin-releasing hormone
<b>HRT</b>	: Hormone replacement therapy
<b>ISA</b>	: Intrinsic sympathetic activity
<b>KDR</b>	: Kinase domain receptor
<b>LH</b>	: Luteinizing hormone
<b>LNG-IUS</b>	: The levonorgestrel intrauterine system
<b>MMPs</b>	: Metalloproteinases
<b>NRP</b>	: Neuropilins
<b>OCPs</b>	: Oral contraceptives
<b>PIGF</b>	: Placenta growth factor
<b>ROS</b>	: Reactive oxygen species
<b>TNF-<math>\alpha</math></b>	: Tumor necrosis factor- $\alpha$
<b>VEGF</b>	: Vascular endothelial growth factor
<b>VSMC</b>	: vascular smooth muscle cell

## List of Figures

<b>No.</b>	<b>Figure</b>	<b>Page</b>
<b><u>1</u></b>	Common locations of endometriosis within the pelvis and abdomen.	<b>6</b>
<b><u>2</u></b>	The American Fertility Society Revised Classification of Endometriosis.	<b>24</b>
<b><u>3</u></b>	The schematic presentation of main metabolic pathways of propranolol in humans. Asterisk indicates the chiral center.	<b>63</b>
<b><u>4</u></b>	The 2nd operation after 4 weeks to examine the peritoneal endometrial implants for size and viability.	<b>74</b>
<b><u>5</u></b>	The last operation after 3 weeks from start the treatment to examine implant and sample collection.	<b>75</b>
<b><u>6</u></b>	Mucosal structure of the endometriosis showing intraglandular acini with dilated blood vessels and few inflammatory cells infiltration in the periphery.	<b>77</b>
<b><u>7</u></b>	Mucosal structure of the endometriosis showing the magnification of (Fig.6) to identify the intact glands, dilated blood vessels and focal inflammatory cells infiltration.	<b>77</b>
<b><u>8</u></b>	Submucosal structure of the endometriosis showing oedema with few inflammatory cells infiltration.	<b>78</b>
<b><u>9</u></b>	Deep submucosa and muscularis of endometriosis showing massive number of inflammatory cells infiltration and congestion of blood vessels.	<b>78</b>



## *List of Figures*

<b><u>No.</u></b>	<b><u>Figure</u></b>	<b><u>Page</u></b>
<b><u>10</u></b>	The blood vessels and capillaries of endometriosis in peritoneum adiposa showing sever dilatation and congestion.	<b>79</b>
<b><u>11</u></b>	The blood vessels and capillaries of endometriosis in peritoneum adiposa showing the magnification of (Fig.10) to identify the dilated blood vessels.	<b>79</b>
<b><u>12</u></b>	The glandular structure of mucosa in endometriosis showing atrophy of the acini.	<b>81</b>
<b><u>13</u></b>	The glandular structure of mucosa in endometriosis showing the magnification of (Fig.11) to identified the atrophy of the acini.	<b>81</b>
<b><u>14</u></b>	The glandular structure of the mucosa in endometriosis showing multinucleated cells.	<b>82</b>
<b><u>15</u></b>	Submucosal layer of the endometriosis showing focal inflammatory cells infiltration with mild dilation of blood vessels.	<b>82</b>
<b><u>16</u></b>	The peritoneum of endometriosis area showing mild dilation of blood vessels with perivascular inflammatory cells infiltration.	<b>83</b>
<b><u>17</u></b>	The peritoneum of endometriosis area showing sever amount of VEGF with perivascular inflammatory cells infiltration.	<b>84</b>
<b><u>18</u></b>	The peritoneum of endometriosis area in the control group showing the magnification of (Fig. 17) to identify the sever amount of VEGF indicated by arrows with perivascular inflammatory cells infiltration.	<b>85</b>

## *List of Figures*

<b><u>No.</u></b>	<b><u>Figure</u></b>	<b><u>Page</u></b>
<b><u>19</u></b>	The peritoneum of endometriosis area in the treatment group showing the mild amount of VEGF indicated by arrows with absence of inflammatory cells.	<b>86</b>
<b><u>20</u></b>	Showing comparison between median of both propranolol treated group endometrial implant compared to control group.	<b>89</b>
<b><u>21</u></b>	Showing comparison between median of both propranolol treated group endometrial implant compared to control group.	<b>90</b>
<b><u>22</u></b>	Showing comparison between propranolol treated group endometrial implant median value compared to control group.	<b>91</b>
<b><u>23</u></b>	Showing the ratio of the endometrial implants before treatment and after treatment.	<b>92</b>

## List of Tables

<b><u>No.</u></b>	<b><u>Table</u></b>	<b><u>Page</u></b>
<b><u>1</u></b>	Pharmacological properties of the different $\beta$ -blockers:	<b>57</b>
<b><u>2</u></b>	The severity of immunohistochemical alteration in the endometriosis of different experimental groups using vascular endothelial growth factor antibodies.	<b>87</b>
<b><u>3</u></b>	Showing the diameter of endometrial implants before treatment in both groups showed non-significant different.	<b>88</b>
<b><u>4</u></b>	Showing the length of the endometrial implants before treatment and after treatment. The treatment group showed significant regression in their length compared to the control group after 3 weeks of treatment.	<b>89</b>
<b><u>5</u></b>	Showing the width of the endometrial implants before treatment and after treatment. The treatment group showed significant regression in their width compared to the control group after 3 weeks of treatment.	<b>90</b>
<b><u>6</u></b>	Showing the height of the endometrial implants before treatment and after treatment. The treatment group showed significant regression in their width compared to the control group after 3 weeks of treatment.	<b>91</b>
<b><u>7</u></b>	Showing the ratio of the endometrial implants before treatment and after treatment.	<b>92</b>

# Introduction

Endometriosis is an estrogen-dependent disease affecting 8% to 10% of females of reproductive age. It is diagnosed in 71% to 87% of females with chronic pelvic pain and in 30% of women with infertility (*McLaren, 2000*), it is defined as adherence and growth of the functional layer of the endometrium outside the uterine cavity.

In Endometriotic lesions, the development of new blood vessels from pre-existing ones is necessary to supply oxygen and essential nutrients (*Fischer et al., 2011*), a process that is coordinated by a sequence of humoral and cellular interactions (*Starkey and Shahidullah, 2011*). Vascular endothelial growth factor (VEGF) is of primary importance as a mediator of angiogenesis in endometriosis in addition to its potent endothelial cell-mitogen-, morphogen-, and vascular permeability-inducing activities (*Vernon and Wilson, 1985; Machado et al., 2010*). Furthermore, metalloproteinases (MMPs) influence the outcome of inflammatory reactions, angiogenesis, and tissue remodeling through regulation of extracellular matrix turnover (*Bertrand et al., 2012; Demirel et al., 2014*).

VEGF is a secreted, heparin-binding homodimeric glycoprotein of ~46 kD, with several protein variants

resulting from alternative splicing of VEGF mRNA (*Houck et al., 1991; Charnock-Jones et al., 1993*). VEGF binds to either one of two tyrosine kinase receptors, the fms-like tyrosine kinase (flt) (*de Vries et al., 1992*) and the kinase domain receptor (KDR) (*Terman et al., 1993*). These receptors are found predominately on endothelial cells (*Ferrara et al., 1992; Jakeman et al., 1992; Connolly et al., 1994*), and activation leads not only to the expression of a number of proteolytic enzymes involved in the process of angiogenesis (*Pepper et al., 1991; Unemor et al., 1992*).

An important mediator of angiogenesis is vascular endothelial growth factor (VEGF)<sup>1</sup>. VEGF is a secreted, heparin-binding homodimeric glycoprotein of ~46 kD, with several protein variants resulting from alternative splicing of VEGF mRNA (*Houck et al., 1991; Charnock-Jones et al., 1993*). VEGF binds to either one of two tyrosine kinase receptors, the fms-like tyrosine kinase (flt) (*de Vries et al., 1992*) and the kinase domain receptor (KDR) (*Terman et al., 1993*). These receptors are found predominately on endothelial cells (*Ferrara, et al., 1992; Jakeman et al., 1992; Connolly et al., 1994*), and activation leads not only to proliferation and increased vascular permeability but also to the expression of a number of proteolytic enzymes involved in the process of angiogenesis (*Pepper et al., 1991; Unemor et al., 1992*).

Propranolol is a non-selective beta-blocker that demonstrates equal affinity for adrenoreceptors and therefore acts on multiple tissues, propranolol has been found to be potent and safe for treatment of hemangiomas by inhibition of angiogenesis (*MacLaren et al., 1996*). Beta-blockers also decrease the expression of VEGF, thus preventing angiogenesis (*Pupo-Nogueira et al., 2007*).

Based on these data, the propranolol inhibits angiogenesis, which plays a critical role in the pathogenesis of endometriosis. Thus, the aim of this study will be to investigate whether propranolol has an inhibitory effect on the angiogenesis of endometriosis in an experimental rat model. For this aim, should evaluate VEGF, MMP2 and MMP9 immunoreactivity in endometriosis lesions.

## **Aim of the Study**

To study the effects of intraperitoneal instillation of propranolol VEGF expression in rat model of surgical induced endometriosis.

### **Research hypothesis:**

In rat model of surgically induced endometriosis, intraperitoneal propranolol instillation may suppress the growth of endometriosis.

### **Research question:**

In rat model for surgically induced endometriosis does intraperitoneal instillation suppress the growth of endometriosis.